|
Malignant tumor of colon
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
miR-21-mediated regulation of 15-hydroxyprostaglandin dehydrogenase in colon cancer.
|
30931980 |
2019 |
|
Malignant tumor of colon
|
0.350 |
Biomarker
|
disease |
BEFREE |
We also examined CBR1 inhibition by oleic acid in cellular levels: The fatty acid effectively inhibited CBR1-mediated 4-oxo-2-nonenal metabolism in colon cancer DLD1 cells and increased sensitivity to doxorubicin in the drug-resistant gastric cancer MKN45 cells that highly express CBR1.
|
28450226 |
2017 |
|
Malignant tumor of colon
|
0.350 |
GeneticVariation
|
disease |
BEFREE |
Genetic variation in 15-hydroxyprostaglandin dehydrogenase and colon cancer susceptibility.
|
23717544 |
2013 |
|
Malignant tumor of colon
|
0.350 |
Biomarker
|
disease |
BEFREE |
Anti-cancer Effects of MW-03, a Novel Indole Compound, by Inducing 15-Hydroxyprostaglandin Dehydrogenase and Cellular Growth Inhibition in the LS174T Human Colon Cancer Cell Line.
|
28966256 |
2017 |
|
Malignant tumor of colon
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
IHC showed CBR1 overexpression in 56 (72%) out of 78 HCC and 88 (72%) out of 123 colon cancer cases.
|
21056497 |
2011 |
|
Liver carcinoma
|
0.320 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemistry (IHC) was performed to analyze CBR1 expression in 78 cases of HCC and 123 cases of colon cancer tissues.
|
21056497 |
2011 |
|
Liver carcinoma
|
0.320 |
AlteredExpression
|
disease |
BEFREE |
Regulation of 15-hydroxyprostaglandin dehydrogenase expression in hepatocellular carcinoma.
|
23954207 |
2013 |
|
Colonic Neoplasms
|
0.310 |
AlteredExpression
|
group |
BEFREE |
15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors.
|
19470469 |
2009 |
|
Malignant neoplasm of prostate
|
0.310 |
GeneticVariation
|
disease |
BEFREE |
The study was to investigate the correlation between rs8752 that located in the 3'untranslated region (UTR) of the 15-hydroxyprostaglandin dehydrogenase (<i>HPGD</i>) gene and prostate cancer (PCa) risk.
|
29187884 |
2017 |
|
Cardiomyopathies
|
0.310 |
GeneticVariation
|
group |
BEFREE |
Among individuals carrying the variant A allele (CBR1:GA/AA and/or CBR3:GA/AA), exposure to low- to moderate-dose anthracyclines (1 to 250 mg/m(2)) did not increase the risk of cardiomyopathy.
|
22124095 |
2012 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
MSI was not detected in the UC-CRN group as compared to 5 (16.7%) in the S-CRN group. p53 mutations occurred in 1 (3.3%) of UC-LR, increasing to 6 (27.3%, P<0.05) and 3 (50%, P<0.05) in the UC-HR subgroups without and with neoplasia respectively, as against 10 (33.3%) in sporadic neoplasia group.
|
22398042 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
15-Hydroxyprostaglandin dehydrogenase is a target of hepatocyte nuclear factor 3beta and a tumor suppressor in lung cancer.
|
18593902 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Loss of 15-hydroxyprostaglandin dehydrogenase indicates a tumor suppressor role in pituitary adenomas.
|
22580984 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
15-Hydroxyprostaglandin dehydrogenase is a tumor suppressor of human gastric cancer.
|
20699658 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
15-Hydroxyprostaglandin dehydrogenase (15-PGDH), a key prostaglandin catabolic enzyme, was recently shown to be a tumor suppressor.
|
21763448 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The qRT-PCR based panel of MYC, MYCN, CCND1, CCND2, EGFR and FNDC3A was successful in detecting neoplasia with an overall accuracy of 54% in S-CRN compared to that of 29% in UC neoplastic samples.
|
27080994 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Subsequently colony formation assays and xenograft tumor mouse model was used to verify the relationship between CBR1 expression and radiosensitivity in HNSCC cells.
|
30376862 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer.
|
16885386 |
2006 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
15-hydroxyprostaglandin dehydrogenase is downregulated and exhibits tumor suppressor activity in gastric cancer.
|
21469975 |
2011 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Using immunocytochemistry, we explored the expression and cellular pattern of CBR 1 and 2 (CB1 and CB2) during prenatal human cortical development, as well as in focal malformations of cortical development associated with intractable epilepsy (focal cortical dysplasia; cortical tubers in patients with the tuberous sclerosis complex and glioneuronal tumors).
|
20621164 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CBR1 overexpression, siRNA, and inhibitors were used to study the role of CBR1 in tumor survival under hypoxia and chemoresistance to cisplatin and doxorubicin in HCC.
|
21056497 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Gene expression of 13 aldo-keto reductases (AKRs), carbonyl reductase 1, and 10 cytochromes P450 (CYPs) was assessed using quantitative real-time polymerase chain reaction in tumors and paired adjacent nonneoplastic tissues from 68 posttreatment breast carcinoma patients.
|
25526449 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The CBR1 siRNA was then injected twice a week into five of the 10 CBR1‑overexpressed OVCAR‑3 tumors.
|
25572536 |
2015 |
|
Malignant Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
15-Hydroxyprostaglandin dehydrogenase as a novel molecular target for cancer chemoprevention and therapy.
|
21856294 |
2011 |
|
Malignant Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
Carbonyl reductase 1 (CBR1) is theorized to participate in various cellular processes, such as signal transduction, apoptosis, carcinogenesis and drug resistance, and is highly expressed in certain malignancies, including lung tumors.
|
29113280 |
2017 |